Continuous dopaminerg stimulation in the treatment of Parkinson's disease;A folyamatos dopaminerg stimuláció jelentocombining double acute accentsége a Parkinson-kór kezelésében

Lege Artis Medicinae

Volumn 18, Issue 8-9, 2008, Pages 585-589

  Annamária, Takáts ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Continuous dopaminerg stimulation; Dyskinesia; Levodopa; Motor fluctuation; Pulsatile effect

Indexed keywords

EID: 53049098765     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Olesen J, Baker MG, Freund T, di Luca M, Mendlewicz J, Ragan I, et al. Consensus document on European brain research. J Neurol Neurosurg Psychiatry 2006;77(Suppl1).
2. Neurological Disorders: public health challenges. World Health Organisation; 2006. p. 140-51.
3. Schapira AHV, Olanow CW. Principles of treatment in Parkinson's disease. Philadelphia: Elsevier Inc.; 2006. p. 338-42.
4. Olanow CW, Obeso JA, Stocchi F. Continuous dopamin receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87.
5. Nutt JG. Continous dopaminergic stimulation: Is it he answer to motor complications of levodopa? Mov Disords 2007;22(1):1-9.
6. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A Clinical and Pharmakokinetic Study. Arch of Neurol 2005;62:905-10.
7. Stocchi F. The levodopa wearing off phenomenon in Parkinson's disease: pharmakokinetic considerations. Expert Opin Pharmacother 2006;7(10):1399-407.
8. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism and Rel Disords 2007;13(8):S13-17.
9. Nyholm D, Lewander T, Johansson A, LeWitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharm 2008;31(2):63-73.
10. Brooks DJ, Leinonen M, Kuoppamaki M, Nissinen H. Five-year efficacy and safety of levodopa/DDCI abd entacapone in patients with Parkinsons disease. J Neural Transm 2008.
11. Cada DJ, Levien T, Baker DE. Rotigotine Transdermal System. Hospital Pharmacy 2007;42(10):939-50.
12. Baldwin CM, Keating GM. Spotlight on rotigotine in Parkinson's disease. Drugs Aging 2008;25(2):175-7.
13. Korczyn AD, Reichmann H, Boroojerdi B, Hack HJ. Rotigotine transdermal system for perioperative administration. J Neural Transm 2007;114:219-21.
14. Steiger M. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease. Eur J Neurol 2008;15:6-15.
15. The Parkinson Study Group. A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease. Arch Neurol 2003;60:1721-8.
16. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study. Neurology 2007;68(16):1262-7.
17. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20.
18. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007;30(5):256-5.
19. Scheller D, Dürmüller N, Moser P, Porsolt RD. Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with sleep - wake cycle int he rat. Eur J Pharmacol 2008. p. 1-7.
20. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release. Neurology 2007;68:1108-15.
21. Isaacson S, Stocchi F, Earl N. Ropinirole 24-hour prolonged release improves sleep disturbance, but does not increase daytime somnolence. 17th World Congress on Parkinson's Disease and Related Disorders. Amsterdam: 2007. Abstracts.
22. Tompson DJ, Vearer D. Steady-state pharmakokinetic properties of a 24-hour prolonged-release formulation of ropinirole. Clin Therapeutics 2007;29:2654-66.
23. Stocchi F, Giorgi I. Efficacy of ropinirol 24-hour prolonged release compared with immediate release formulation in eraly PD: the EASE-PD study. 10th Congress of the EFNS. Glagow: 2006. Abstracts.
24. Watts RL, Sethi K, Pahwa R, Adams B, Earl N. Ropinirole 24-hour prolonged release delays the onset of dyskinesia compared with carbidopa - levodopa in patients with Parkinson's disease treated with levodopa. 11th Congress of the EFNS. Brüsszel: 2007. Abstracts.
25. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson's disease. State of the Art in 2004. Clin Neuropharmacol 2004;27:245-56.
26. Quinn N, Parkes JD, Marden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-6.
27. Kurlan R, Rubin Aj, Miller C. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism. Ann Neurol 1986;20:262-5.
28. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8(5):657-64.
29. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurotherapeutics 2006;6(10):1403-11.
30. Wolters ECh. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism and Rel Disords 2007;13(S18-23).
31. Ostergaard K, Sunde N, Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 2002;17849:693-700.
32. Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonisn Relat Disord 2006;12(5):265-72.
33. Takáts A. Néhány új szempont a Parkinson-kór gyógyszeres kezelésében 2007-ben. Gyógyszereink 2007;5-6:147-50.